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Nanotechnology has made important contributions to oncology over the past decades. 
Although encapsulating drugs in liposomes has been broadly shown to improve PK and 
biodistribution, as yet no marketed liposomal therapeutic agents have exhibited an overall 
survival benefit when directly compared with the conventional parent drug. 
The lack of or limited gain in overall survival challenges the field to improve patient survival 
further with more effective nanomedicine-based therapies.  
Up to now, nanomedicine research projects have been structured to adapt the physico-
chemical parameters of a delivery system – loading, chemistry, size, charge, surface 
modification – to control its in vivo behaviour. Many experimental scientists, 
pharmacologists and nanotechnology engineers have held to the premise that solid tumors 
consist of uniform tissues.  
In fact, human tumors are highly diverse and heterogeneous; they vary in pathological 
characteristics, size less than 1 mm to above 10 cm, metastatic or primary tumor… 
Even experimental rodent tumors and implanted tumors, or those of orthotopic or 
autochthonous origin, exhibit these different characteristics. 
The complex physiological and pathophysiological interactions between NPs and biological 
systems, which are unique to individual patients, have hampered the clinical translation of 
cancer nanomedicine 
Therefore, the effects of heterogeneity of human tumors should be better understood. This 
conference will discuss some of these complexities to understand and consider for effective 
nanomedicine development. 
